Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease
NCT00312052 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease
- Lead sponsor
- Eisai Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2007
- Completion date
- August 31, 2009
- Enrollment
- 720 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.